These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 36223118)

  • 1. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
    Frost MC; Zhang L; Kim HM; Lin LA
    JAMA Netw Open; 2022 Oct; 5(10):e2236298. PubMed ID: 36223118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
    Lin LA; Zhang L; Kim HM; Frost MC
    Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.
    Nguyen B; Zhao C; Bailly E; Chi W
    J Gen Intern Med; 2024 Jan; 39(1):95-102. PubMed ID: 37670069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall and Telehealth Addiction Treatment Utilization by Age, Race, Ethnicity, and Socioeconomic Status in California After COVID-19 Policy Changes.
    Palzes VA; Chi FW; Metz VE; Sterling S; Asyyed A; Ridout KK; Campbell CI
    JAMA Health Forum; 2023 May; 4(5):e231018. PubMed ID: 37204804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
    JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
    Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
    J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA; Sarpong A; Sistad R; Roth C; Banducci AN; Simpson T; Hyde J; Davenport M; Weisberg R
    J Subst Use Addict Treat; 2024 Jan; 156():209188. PubMed ID: 37866437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telehealth and delivery of alcohol use disorder treatment in the Veterans Health Administration.
    Perumalswami PV; Adams MA; Frost MC; Holleman R; Kim HM; Zhang L; Lin LA
    Alcohol Clin Exp Res (Hoboken); 2024 May; 48(5):944-954. PubMed ID: 38529689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
    JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
    Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
    J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
    J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.
    Lin LA; Fortney JC; Bohnert ASB; Coughlin LN; Zhang L; Piette JD
    J Subst Abuse Treat; 2022 Feb; 133():108492. PubMed ID: 34175175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
    Textor L; Ventricelli D; Aronowitz SV
    Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telehealth for opioid use disorder: retention as a function of demographics and rurality.
    Williams AR; Aronowitz SV; Rowe C; Gallagher R; Behar E; Bisaga A
    Am J Drug Alcohol Abuse; 2023 Mar; 49(2):260-265. PubMed ID: 36961998
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient Use and Clinical Practice Patterns of Remote Cardiology Clinic Visits in the Era of COVID-19.
    Yuan N; Pevnick JM; Botting PG; Elad Y; Miller SJ; Cheng S; Ebinger JE
    JAMA Netw Open; 2021 Apr; 4(4):e214157. PubMed ID: 33818619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.